You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Dow
Mallinckrodt
McKesson
Moodys

Last Updated: April 11, 2021

DrugPatentWatch Database Preview

Litigation Details for Spectrum Pharmaceuticals, Inc. v. Sandoz Inc. (D. Nev. 2012)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Spectrum Pharmaceuticals, Inc. v. Sandoz Inc.
The small molecule drug covered by the patent cited in this case is   Start Trial .

Details for Spectrum Pharmaceuticals, Inc. v. Sandoz Inc. (D. Nev. 2012)

Date Filed Document No. Description Snippet Link To Document
2014-12-28 313 continuation 12 applications. (See U.S. Patent No. 6,500,829). The ’829 Patent issued with fourteen (14) 13 …commonly used chemotherapy agent. U.S. Patent No. 22 6,500,829 col.1 ll.22–24 (filed Apr. 18, 1995). …amount of 25 2000 mg per dose.” See U.S. Patent No. 6,500,829 col.9 ll.55, 63–64. This Court construed…administered in divided 6 dose.” U.S. Patent No. 6,500,829 col.5 ll.15–21. This portion of the specification…granted on October 2, 5 2012. (See U.S. Patent No. 6,500,829). 6 Defendant asserts that Plaintiffs External link to document
2015-02-24 368 18 of claims 1 and 2 of U.S. Patent No. 6,500,829 (the “’829 patent”). Having considered the 19 parties…inventors of the ’829 patent also obtained U.S. Patent No. 4,959,472 (the “’472 4 patent”), which is directed…Cosulich ’018 Patent (PTX 15) 16 91. U.S. Patent No. 2,688,018 (the “’018 patent”) issued on August… regarding the ’829 patent, which asserts that the claims of the 18 ’829 patent are invalid, unenforceable…)). 23 B. THE ’829 PATENT 24 27. The ’829 patent is titled “Substantially Pure Diastereoisomers External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Colorcon
McKinsey
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.